{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T13:15:11Z","timestamp":1775826911158,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07916-6","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:34:07Z","timestamp":1772627647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DKC1: a robust prognostic factor and potential therapeutic target in multiple myeloma"],"prefix":"10.1186","volume":"24","author":[{"given":"Chenxi","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Likun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexiao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7872-8960","authenticated-orcid":false,"given":"Chengyun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"1","key":"7916_CR1","doi-asserted-by":"publisher","first-page":"14564","DOI":"10.1038\/s41598-024-65590-4","volume":"14","author":"DT Zhu","year":"2024","unstructured":"Zhu DT, Park A, Lai A, Zhang L, Attar H, Rebbeck TR. Multiple myeloma incidence and mortality trends in the United States, 1999-2020. Sci Rep. 2024;14(1):14564.","journal-title":"Sci Rep"},{"key":"7916_CR2","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"issue":"27","key":"7916_CR3","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1200\/JCO.21.01217","volume":"40","author":"D Hofste Op Bruinink","year":"2022","unstructured":"Hofste Op Bruinink D, Kuiper R, van Duin M, Cupedo T, van der Velden VHJ, Hoogenboezem R, et al. Identification of high-risk multiple myeloma with a plasma cell leukemia-like transcriptomic profile. J Clin Oncol. 2022;40(27):3132\u201350.","journal-title":"J Clin Oncol"},{"issue":"7","key":"7916_CR4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.22.01226","volume":"41","author":"T Jelinek","year":"2023","unstructured":"Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma. J Clin Oncol. 2023;41(7):1383\u201392.","journal-title":"J Clin Oncol"},{"key":"7916_CR5","doi-asserted-by":"crossref","unstructured":"Pinto V, Bergantim R, Caires HR, Seca H, Guimar\u00e3es JE, Vasconcelos MH. Multiple myeloma: available therapies and causes of drug resistance. Cancers. 2020;12(2).","DOI":"10.3390\/cancers12020407"},{"key":"7916_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199\u2013208.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"7916_CR7","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1261\/rna.078953.121","volume":"27","author":"A Garus","year":"2021","unstructured":"Garus A, Autexier C. Dyskerin: an essential pseudouridine synthase with multifaceted roles in ribosome biogenesis, splicing, and telomere maintenance. RNA. 2021;27(12):1441\u201358.","journal-title":"RNA"},{"issue":"6761","key":"7916_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/990141","volume":"402","author":"JR Mitchell","year":"1999","unstructured":"Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999;402(6761):551\u201355.","journal-title":"Nature"},{"issue":"12","key":"7916_CR9","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.4161\/15476286.2014.972855","volume":"11","author":"YT Yu","year":"2014","unstructured":"Yu YT, Meier UT. RNA-guided isomerization of uridine to pseudouridine-pseudouridylation. RNA Biol. 2014;11(12):1483\u201394.","journal-title":"RNA Biol"},{"issue":"5604","key":"7916_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1126\/science.1079447","volume":"299","author":"D Ruggero","year":"2003","unstructured":"Ruggero D, Grisendi S, Piazza F, Rego E, Mari F, Rao PH, et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science. 2003;299(5604):259\u201362.","journal-title":"Science"},{"key":"7916_CR11","doi-asserted-by":"crossref","unstructured":"MacNeil DE, Bensoussan HJ, Autexier C. Telomerase regulation from beginning to the end. Genes. 2016;7(9).","DOI":"10.3390\/genes7090064"},{"issue":"6","key":"7916_CR12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s11427-014-4666-6","volume":"57","author":"F Kong","year":"2014","unstructured":"Kong F, Zheng C, Xu D. Telomerase as a \u201cstemness\u201d enzyme. Sci China Life Sci. 2014;57(6):564\u201370.","journal-title":"Sci China Life Sci"},{"issue":"4","key":"7916_CR13","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1046\/j.1365-2141.2000.02109.x","volume":"110","author":"I Dokal","year":"2000","unstructured":"Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol. 2000;110(4):768\u201379.","journal-title":"Br J Haematol"},{"key":"7916_CR14","doi-asserted-by":"publisher","first-page":"1592135","DOI":"10.3389\/fcell.2025.1592135","volume":"13","author":"C Sun","year":"2025","unstructured":"Sun C, Liu X, Liu T, Fan C, Jiang Y, Li B, et al. Comprehensive analyses of telomerase component DKC1 and its association with clinical, molecular and immune landscapes in uterine corpus endometrial carcinoma. Front Cell Dev Biol. 2025;13:1592135.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"7916_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/path.2023","volume":"210","author":"L Montanaro","year":"2006","unstructured":"Montanaro L, Brigotti M, Clohessy J, Barbieri S, Ceccarelli C, Santini D, et al. Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J Pathol. 2006;210(1):10\u201318.","journal-title":"The J Pathol"},{"key":"7916_CR16","doi-asserted-by":"crossref","unstructured":"Liu B, Zhang J, Huang C, Liu H. Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis. PLoS One. 2012;7(8):e43147.","DOI":"10.1371\/journal.pone.0043147"},{"issue":"12","key":"7916_CR17","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1158\/0008-5472.CAN-15-0879","volume":"76","author":"R O\u2019Brien","year":"2016","unstructured":"O\u2019Brien R, Tran SL, Maritz MF, Liu B, Kong CF, Purgato S, et al. MYC-driven neuroblastomas are addicted to a telomerase-independent function of dyskerin. Cancer Res. 2016;76(12):3604\u201317.","journal-title":"Cancer Res"},{"issue":"10","key":"7916_CR18","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41416-020-01045-7","volume":"123","author":"KA Elsharawy","year":"2020","unstructured":"Elsharawy KA, Mohammed OJ, Aleskandarany MA, Hyder A, El-Gammal HL, Abou-Dobara MI, et al. The nucleolar-related protein dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer. Br J Cancer. 2020;123(10):1543\u201352.","journal-title":"Br J Cancer"},{"issue":"5","key":"7916_CR19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41416-019-0695-z","volume":"122","author":"P Hou","year":"2020","unstructured":"Hou P, Shi P, Jiang T, Yin H, Chu S, Shi M, et al. DKC1 enhances angiogenesis by promoting HIF-1\u03b1 transcription and facilitates metastasis in colorectal cancer. Br J Cancer. 2020;122(5):668\u201379.","journal-title":"Br J Cancer"},{"issue":"14","key":"7916_CR20","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.1158\/0008-5472.CAN-09-4730","volume":"70","author":"C Bellodi","year":"2010","unstructured":"Bellodi C, Krasnykh O, Haynes N, Theodoropoulou M, Peng G, Montanaro L, et al. Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res. 2010;70(14):6026\u201335.","journal-title":"Cancer Res"},{"key":"7916_CR21","doi-asserted-by":"crossref","unstructured":"Andrades E, Toll A, Deza G, Segura S, Gimeno R, Espadas G, et al. Loss of dyskerin facilitates the acquisition of metastatic traits by altering the mevalonate pathway. Life Sci Alliance. 2023;6(4).","DOI":"10.26508\/lsa.202201692"},{"key":"7916_CR22","volume-title":"The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities","author":"E-O Ramberger","year":"2662","unstructured":"Ramberger EA-O, Sapozhnikova V, Ng YLD, Dolnik A, Ziehm MA-O, Popp O, et al. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Electronic; 2662-1347."},{"issue":"1","key":"7916_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40644-024-00705-8","volume":"24","author":"Y Yu","year":"2024","unstructured":"Yu Y, Guo H, Zhang M, Hou F, Yang S, Huang C, et al. Multi-institutional validation of a radiomics signature for identification of postoperative progression of soft tissue sarcoma. Cancer Imag. 2024;24(1):59.","journal-title":"Cancer Imag"},{"key":"7916_CR24","unstructured":"Therneau TM, Atkinson EJ. An introduction to recursive partitioning using the RPART routines. Mayo Foundation. 2022."},{"key":"7916_CR25","unstructured":"Zhang YA-O, Wong GA-O, Mann G-AOX, Muller S-O, Yang J-O. SurvBenchmark: comprehensive benchmarking study of survival analysis methods using both omics data and clinical data. 2047-217X (Electronic)."},{"key":"7916_CR26","doi-asserted-by":"crossref","unstructured":"Rocchi L, Barbosa AJ, Onofrillo C, Del Rio A, Montanaro L. Inhibition of human dyskerin as a new approach to target ribosome biogenesis. PLoS One. 2014;9(7):e101971.","DOI":"10.1371\/journal.pone.0101971"},{"key":"7916_CR27","doi-asserted-by":"crossref","unstructured":"Borowicz S, Van Scoyk M, Avasarala S, Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK, et al. The soft agar colony formation assay. J Vis Exp. 2014;92:e51998.","DOI":"10.3791\/51998-v"},{"issue":"1","key":"7916_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12935-024-03304-6","volume":"24","author":"H Luo","year":"2024","unstructured":"Luo H, Pan C, Wang L, Zheng L, Cao S, Hu X, et al. Low TYROBP expression predicts poor prognosis in multiple myeloma. Cancer Cell Int. 2024;24(1):117.","journal-title":"Cancer Cell Int"},{"key":"7916_CR29","unstructured":"Kan G, Wang ZA-O, Sheng CA-O, Chen G, Yao C, Mao Y, et al. Dual inhibition of DKC1 and MEK1\/2 synergistically restrains the growth of colorectal cancer cells. (2198-3844 (Electronic)."},{"issue":"3","key":"7916_CR30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41587-022-01505-w","volume":"41","author":"Q Dai","year":"2023","unstructured":"Dai Q, Zhang LS, Sun HL, Pajdzik K, Yang L, Ye C, et al. Quantitative sequencing using BID-seq uncovers abundant pseudouridines in mammalian mRNA at base resolution. Nat Biotechnol. 2023;41(3):344\u201354.","journal-title":"Nat Biotechnol"},{"issue":"37","key":"7916_CR31","doi-asserted-by":"publisher","first-page":"9754","DOI":"10.1021\/bi00088a030","volume":"32","author":"A Bakin","year":"1993","unstructured":"Bakin A, Ofengand J. Four newly located pseudouridylate residues in Escherichia coli 23S ribosomal RNA are all at the peptidyltransferase center: analysis by the application of a new sequencing technique. Biochemistry. 1993;32(37):9754\u201362.","journal-title":"Biochemistry"},{"key":"7916_CR32","doi-asserted-by":"crossref","unstructured":"Chang Y, Jin H, Cui Y, Yang F, Chen K, Kuang W, et al. PUS7-dependent pseudouridylation of ALKBH3 mRNA inhibits gastric cancer progression. Clin Transl Med. 2024;14(8):e 1811.","DOI":"10.1002\/ctm2.1811"},{"issue":"47","key":"7916_CR33","doi-asserted-by":"publisher","first-page":"14878","DOI":"10.1002\/anie.201708276","volume":"56","author":"Z Lei","year":"2017","unstructured":"Lei Z, Yi C. A radiolabeling-free, qPCR-based method for locus-specific pseudouridine detection. Angew Chem Int Ed. 2017;56(47):14878\u201382.","journal-title":"Angew Chem Int Ed"},{"issue":"1","key":"7916_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","volume":"17","author":"J Xu","year":"2024","unstructured":"Xu J, Wang BY, Yu SH, Chen SJ, Yang SS, Liu R, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024;17(1):23.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"7916_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","volume":"12","author":"P Hagen","year":"2022","unstructured":"Hagen P, Zhang J, Barton K. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J. 2022;12(5):83.","journal-title":"Blood Cancer J"},{"issue":"4","key":"7916_CR36","first-page":"1008","volume":"4","author":"H Black","year":"2021","unstructured":"Black H, Glavey S. Gene expression profiling as a prognostic tool in multiple myeloma. Cancer Drug Resist. 2021;4(4):1008\u201318.","journal-title":"Cancer Drug Resist"},{"issue":"11","key":"7916_CR37","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26(11):2406\u201313.","journal-title":"Leukemia"},{"issue":"6","key":"7916_CR38","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy Jr","year":"2007","unstructured":"Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276\u201384.","journal-title":"Blood"},{"issue":"4","key":"7916_CR39","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/cells11040739","volume":"11","author":"M Walter","year":"2022","unstructured":"Walter M, Herr P. Re-discovery of pyrimidine salvage as target in cancer therapy. Cells. 2022;11(4):739.","journal-title":"Cells"},{"issue":"1","key":"7916_CR40","first-page":"139","volume":"63","author":"DS Carroll","year":"1979","unstructured":"Carroll DS, Kemeny NE, Gralla RJ. Phase II evaluation of pyrazofurin in patients with advanced colorectal carcinoma. Cancer Treat Rep. 1979;63(1):139\u201340.","journal-title":"Cancer Treat Rep"},{"issue":"10","key":"7916_CR41","first-page":"1569","volume":"62","author":"WR Vogler","year":"1978","unstructured":"Vogler WR, Trulock PD. Phase I study of pyrazofurin in refractory acute myelogenous leukemia. Cancer Treat Rep. 1978;62(10):1569\u201371.","journal-title":"Cancer Treat Rep"},{"issue":"10","key":"7916_CR42","first-page":"1573","volume":"62","author":"RJ Gralla","year":"1978","unstructured":"Gralla RJ, Sordillo PP, Magill GB. Phase II evaluation of pyrazofurin in patients with metastatic sarcoma. Cancer Treat Rep. 1978;62(10):1573\u201374.","journal-title":"Cancer Treat Rep"},{"key":"7916_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/B978-0-444-00377-5.50018-2","volume-title":"Progress in myeloma","author":"M Vrana","year":"1980","unstructured":"Vrana M, Bunn PA. A review of therapeutic trials in multiple myeloma and perspectives for future trials. In: Potter M, editor. Progress in myeloma. Amsterdam: Elsevier; 1980. p. 239\u201362."},{"issue":"7","key":"7916_CR44","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/14728222.2025.2537416","volume":"29","author":"R Vilarullo","year":"2025","unstructured":"Vilarullo R, Casco MDP, Mares Ahlers MC, Gottifredi V, Balcone L, Maggio J, et al. Improving therapeutic strategies for triple-negative breast cancer: synergistic effects of DKC1 inhibition and paclitaxel. Expert Opin Ther Targets. 2025;29(7):491\u2013504.","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"7916_CR45","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.celrep.2013.04.030","volume":"3","author":"C Bellodi","year":"2013","unstructured":"Bellodi C, McMahon M, Contreras A, Juliano D, Kopmar N, Nakamura T, et al. H\/ACA small RNA dysfunctions in disease reveal key roles for noncoding RNA modifications in hematopoietic stem cell differentiation. Cell Rep. 2013;3(5):1493\u2013502.","journal-title":"Cell Rep"},{"key":"7916_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-genet-112618-043830","volume":"54","author":"EK Borchardt","year":"2020","unstructured":"Borchardt EK, Martinez NM, Gilbert WV. Regulation and function of RNA pseudouridylation in human cells. Annu Rev Genet. 2020;54:309\u201336.","journal-title":"Annu Rev Genet"},{"issue":"17","key":"7916_CR47","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1128\/MCB.00531-10","volume":"30","author":"C Chen","year":"2010","unstructured":"Chen C, Zhao X, Kierzek R, Yu YT. A flexible RNA backbone within the polypyrimidine tract is required for U2AF65 binding and pre-mRNA splicing in vivo. Mol Cell Biol. 2010;30(17):4108\u201319.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"7916_CR48","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3 K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833\u201340.","journal-title":"Mol Ther"},{"key":"7916_CR49","doi-asserted-by":"publisher","first-page":"654370","DOI":"10.3389\/fmicb.2021.654370","volume":"12","author":"DP Czekay","year":"2021","unstructured":"Czekay DP, Kothe U. H\/ACA small ribonucleoproteins: structural and functional comparison between archaea and eukaryotes. Front Microbiol. 2021;12:654370.","journal-title":"Front Microbiol"},{"issue":"18","key":"7916_CR50","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1016\/j.cell.2025.05.032","volume":"188","author":"M B\u00e9routi","year":"2025","unstructured":"B\u00e9routi M, Wagner M, Greulich W, Piseddu I, G\u00e4rtig J, Hansbauer L, et al. Pseudouridine RNA avoids immune detection through impaired endolysosomal processing and TLR engagement. Cell. 2025;188(18):4880\u201395.e15.","journal-title":"Cell"},{"issue":"1","key":"7916_CR51","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cell.2014.08.028","volume":"159","author":"S Schwartz","year":"2014","unstructured":"Schwartz S, Bernstein DA, Mumbach MR, Jovanovic M, Herbst RH, Le\u00f3n-Ricardo BX, et al. Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. Cell. 2014;159(1):148\u201362.","journal-title":"Cell"},{"issue":"1","key":"7916_CR52","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.tibs.2023.10.008","volume":"49","author":"R Rodell","year":"2024","unstructured":"Rodell R, Robalin N, Martinez NM. Why U matters: detection and functions of pseudouridine modifications in mRNAs. Trends Biochem Sci. 2024;49(1):12\u201327.","journal-title":"Trends Biochem Sci"},{"issue":"14","key":"7916_CR53","doi-asserted-by":"publisher","first-page":"6784","DOI":"10.1073\/pnas.1817334116","volume":"116","author":"V Khoddami","year":"2019","unstructured":"Khoddami V, Yerra A, Mosbruger TL, Fleming AM, Burrows CJ, Cairns BR. Transcriptome-wide profiling of multiple RNA modifications simultaneously at single-base resolution. Proc Natl Acad Sci USA. 2019;116(14):6784\u201389.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7525","key":"7916_CR54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nature13802","volume":"515","author":"TM Carlile","year":"2014","unstructured":"Carlile TM, Rojas-Duran MF, Zinshteyn B, Shin H, Bartoli KM, Gilbert WV. Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. Nature. 2014;515(7525):143\u201346.","journal-title":"Nature"},{"issue":"8","key":"7916_CR55","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nchembio.1836","volume":"11","author":"X Li","year":"2015","unstructured":"Li X, Zhu P, Ma S, Song J, Bai J, Sun F, et al. Chemical pulldown reveals dynamic pseudouridylation of the mammalian transcriptome. Nat Chem Biol. 2015;11(8):592\u201397.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"7916_CR56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-023-00139-x","volume":"4","author":"L Qiu","year":"2023","unstructured":"Qiu L, Jing Q, Li Y, Han J. RNA modification: mechanisms and therapeutic targets. Mol Biomed. 2023;4(1):25.","journal-title":"Mol Biomed"},{"issue":"18","key":"7916_CR57","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1128\/MCB.22.18.6321-6335.2002","volume":"22","author":"C Vinson","year":"2002","unstructured":"Vinson C, Myakishev M, Acharya A, Mir AA, Moll JR, Bonovich M. Classification of human B-ZIP proteins based on dimerization properties. Mol Cell Biol. 2002;22(18):6321\u201335.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"7916_CR58","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/sj.onc.1209116","volume":"25","author":"JM Angelastro","year":"2006","unstructured":"Angelastro JM, Canoll PD, Kuo J, Weicker M, Costa A, Bruce JN, et al. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. Oncogene. 2006;25(6):907\u201316.","journal-title":"Oncogene"},{"issue":"9","key":"7916_CR59","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/ijc.22469","volume":"120","author":"SE Monaco","year":"2007","unstructured":"Monaco SE, Angelastro JM, Szabolcs M, Greene LA. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int. J Cancer. 2007;120(9):1883\u201390.","journal-title":"Int. J Cancer"},{"issue":"9","key":"7916_CR60","doi-asserted-by":"publisher","first-page":"7705","DOI":"10.1074\/jbc.M110.207639","volume":"286","author":"D Dluzen","year":"2011","unstructured":"Dluzen D, Li G, Tacelosky D, Moreau M, Liu DX. BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner. J Biol Chem. 2011;286(9):7705\u201313.","journal-title":"J Biol Chem"},{"issue":"6","key":"7916_CR61","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nm.2158","volume":"16","author":"Z Sheng","year":"2010","unstructured":"Sheng Z, Li L, Zhu LJ, Smith TW, Demers A, Ross AH, et al. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med. 2010;16(6):671\u201377.","journal-title":"Nat Med"},{"key":"7916_CR62","doi-asserted-by":"crossref","unstructured":"Gupta A, Bansal M, Ding J, Karki S, Pandit M, Sudarshan S, et al. DKC1-mediated pseudouridylation of rRNA targets hnRNP A1 to sustain IRES-dependent translation and ATF4-driven metabolic adaptation. Sci Adv. 2025;11(35):eadv 9401.","DOI":"10.1126\/sciadv.adv9401"},{"issue":"4","key":"7916_CR63","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.molcel.2023.01.009","volume":"83","author":"H Adachi","year":"2023","unstructured":"Adachi H, Pan Y, He X, Chen JL, Klein B, Platenburg G, et al. Targeted pseudouridylation: an approach for suppressing nonsense mutations in disease genes. Mol Cell. 2023;83(4):637\u201351.e9.","journal-title":"Mol Cell"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07916-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07916-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07916-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:03:58Z","timestamp":1775822638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07916-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7916"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07916-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The human samples and animal experiments were approved by the Ethics Committee of the Second Qilu Hospital of Shandong University (no. KYLL2024737) and were conducted in accordance with legal requirements and national guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"497"}}